Small bowel adenocarcinomas complicating Crohn's disease are associated with dysplasia: a pathological and molecular study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Svrcek Magali, Piton Gael, Cosnes Jacques, Beaugerie Laurent, Vermeire Severine, Geboes Karel, Lemoine Antoinette, Cervera Pascale, El-Murr Nizar, Dumont Sylvie, Scriva Aurélie, Lascols Olivier, Ardizzone Sandro, Fociani Paolo, Savoye Guillaume, Le Pessot Florence, Novacek Gottfried, Wrba Fritz, Colombel Jean-Frédéric, Leteurtre Emmanuelle, Bouhnik Yoram, Cazals-Hatem Dominique, Cadiot Guillaume, Diebold Marie-Danièle, Rahier Jean-François, Delos Monique, Fléjou Jean-François, Carbonnel Franck
Аннотация
METHODS: Forty-five SBA complicating CD and 4 specimens with dysplasia without SBA were screened. In SBA, we looked for dysplasia and determined their pathological characteristics (type, grade, distribution). We also stained for mismatch repair proteins (MLH1, MSH2, MSH6, PMS2), p53, β-catenin, and p16 and looked for KRAS, BRAF and PIK3CA mutations.
RESULTS: All neoplastic lesions, except 1 lesion, were found in inflamed mucosal areas. Dysplasia was found in 20 of 41 patients with SBA (49%). Dysplasia was flat or raised, low grade or high grade, and adjacent or distant to concomitant SBA. Molecular markers of SBA carcinogenesis complicating CD were similar to those observed in chronic colitis-related colorectal cancer (KRAS, BRAF, p53, MSI), although differences were observed for β-catenin and p16. No PIK3CA mutations were observed.
CONCLUSIONS: These results suggest that there is an inflammation-dysplasia-adenocarcinoma sequence in at least half of CD-related SBA, similar to what is observed in chronic colitis-related colorectal cancer and may have implications for the prevention and treatment of this cancer.